Context Radiolabelled choline positron emission tomography has changed the
management of prostate cancer patients. However, new emerging radiopharmaceutical …

Background Positron emission tomography/computed tomography (PET/CT) has recently
emerged as a promising diagnostic imaging platform for prostate cancer. Several …

Cancer cells do reprogram their energy metabolism to enable several functions, such as
generation of biomass including membrane biosynthesis, and overcoming bioenergetic and …

Prostate-specific antigen (PSA) is currently the most widely used biomarker of prostate
cancer (PCa). PSA suggests the presence of primary tumour and disease relapse after …

18 F-fluorocholine is a specific promising agent for imaging tumor cell proliferation,
particularly in prostate cancer, using PET/CT. It is a beneficial tool in the early detection of …

Purpose The role of 18F–choline positron emission tomography/computed tomography
(FCH-PET/CT) in patients with metastatic castration-resistant prostate cancer (mCRPC) has …

Aim: High rate of non-target lesions in metastatic castration-resistant prostate cancer usually
limits applicability of Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and …

Imaging has played an important part in the diagnosis of disease and development of the
understanding of the underlying disease mechanisms and is now poised to make an impact …

Purpose Defining an optimal imaging modality for assessment of therapy and the best time
of evaluation are pivotal for ideal patient's management. Methods 223 Ra (Xofigo®, formerly …

Purpose To characterize intermediate and high-risk prostate carcinomas with measurements
of standardized uptake values (SUVs) and apparent diffusion coefficient (ADC) values by …